Skip To Main Content
Xiaoying Ma on Muck Rack

Xiaoying Ma

As seen in: Nature, Wiley Online Library, PLOS ONE, Frontiers, MDPI, Taylor & Francis Online, ACS Publications, Journal of Translational Medicine, Royal Society of Chemistry, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiaoying

Contact Xiaoying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Reduced BCL2 level in astrocytes contributes to blood-brain barrier disruption in the striatum of offspring exposed to maternal preeclampsia

|
By Jiashuo Zhang, Mengting Zhang, Zhengyang Zhao, Min Xie, Menghan Wei, Siyi Liu Verified, Yulu Wu, Shiwan Tao, Qiuyue Lv, Xiaoying Ma, Yunqi Huang, Min Zou, Qiang Wang
| Nature Verified
Abstract Maternal preeclampsia (PE) contributes to neurodevelopmental disorders. However, the underlying molecular mechanism remains unclear. We investigated the potential biological regulatory mechanisms by establishing an animal model and primary cell culture. Data from the Adolescent Brain Cognitive Development human study revealed that the striatum mediates maternal PE and offspring behavioral disorders.
Open in Who Shared Issue with article?

In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial - Nature Medicine

|
By Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu, Wensu Yu, Michael Ott, Zi Wang, Yuxuan Wu, Taihua Yang, Qiang Xia
| Nature Verified
Abstract Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction.
Open in Who Shared Issue with article?

Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation

|
By Xiaoying Ma, Hui Wang, Shengyan Dang
| Dove Medical Press
Back to Journals » Breast Cancer: Targets and Therapy » Volume 18 Authors Ma X , Dang S, Wang H, Xia L, Ma P, Qi Y Received 26 February 2026 Accepted for publication 20 May 2026 Published 24 June 2026 Volume 2026:18 605051 DOI https://doi.org/10.2147/BCTT.S605051 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Harikrishna Nakshatri Xiaoying Ma,1– 3 Shengyan Dang,1,3,4 Hui Wang,3,4 Lei Xia,2 Ping Ma,2 Yujuan...
Open in Who Shared Issue with article?
See all 17 articles